Oxford Biomedica’s (OXB) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their hold rating on shares of Oxford Biomedica (LON:OXB) in a report released on Wednesday morning,Digital Look reports. The brokerage currently has a GBX 595 price target on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on OXB. Royal Bank Of Canada reduced their price target on shares of Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a research report on Monday, August 10th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Oxford Biomedica has a consensus rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Stock Performance

Shares of OXB opened at GBX 435 on Wednesday. The company has a 50-day moving average of GBX 555.19 and a two-hundred day moving average of GBX 599.92. The stock has a market cap of £526.51 million, a price-to-earnings ratio of -16.16 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. Oxford Biomedica has a one year low of GBX 420 and a one year high of GBX 952.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.